Literature DB >> 8406354

Genetic predispositions for the immunological features of chronic active hepatitis.

A J Czaja1, H A Carpenter, P J Santrach, S B Moore.   

Abstract

To assess the frequency and genetic predispositions of concurrent immunological diseases and immunoserological markers in autoimmune hepatitis and chronic viral hepatitis, we assessed 185 patients prospectively, including 122 patients with autoimmune hepatitis and 63 patients with viral disease. Human leukocyte antigens were determined in all patients. Sixty patients (32%) had concurrent immunological diseases, and the majority of the diseases (68%) had known human leukocyte antigen associations. Although patients with autoimmune hepatitis had concurrent immunological diseases more commonly than those with viral disease (38% vs. 22%; p = 0.04), the nature of the diseases was similar in both groups, as were the frequencies of human leukocyte antigen-DR4 (42% vs. 39%; p = 0.7). The presence of human leukocyte antigen-DR4 was associated with the concurrence of immunological diseases in both autoimmune (62% vs. 33%; p = 0.01) and viral hepatitis (75% vs. 29%; p = 0.009). In autoimmune hepatitis, human leukocyte antigen-DR4 was also associated with the expression of smooth muscle antibodies and high-titer antinuclear antibodies. We conclude that concurrent immunological diseases and immunoserological markers are common in autoimmune and chronic viral hepatitis. Both conditions have a common genetic predisposition for concurrent immunological disease associated with human leukocyte antigen-DR4. The expression of smooth muscle antibodies and high-titer antinuclear antibodies is associated with human leukocyte antigen-DR4 in autoimmune hepatitis only, suggesting that this response is associated with triggering antigens and immune recognition systems that are different from those in viral disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406354     DOI: 10.1002/hep.1840180411

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  24 in total

Review 1.  Genetic bases of autoimmune hepatitis.

Authors:  Albert J Czaja; Derek G Doherty; Peter T Donaldson
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

2.  Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis.

Authors:  Albert J Czaja; Zakera Shums; Peter T Donaldson; Gary L Norman
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

3.  Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association.

Authors:  S Parveen; S A Morshed; K Arima; M Nishioka; A J Czaja; W C Chow; H S Ng
Journal:  Dig Dis Sci       Date:  1998-06       Impact factor: 3.199

4.  Hepatic dysfunction in hyperthyroidism.

Authors:  Saro Khemichian; Tse-Ling Fong
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-05

Review 5.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

6.  Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease.

Authors:  Agustin Castiella; Eva Zapata; M Isabel Lucena; Raúl J Andrade
Journal:  World J Hepatol       Date:  2014-04-27

7.  Frequency and significance of phenotypes for alpha1-antitrypsin deficiency in type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

Review 8.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

Review 9.  Drug therapy in the management of type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

Review 10.  Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly.

Authors:  Albert J Czaja
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.